PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10399798

Microscopic polyangiitis presenting as schizophrenia.

A Askari·A Saadeh·N I Buheis
View original source ↗Export metadata ↓

Abstract

Primary vasculitides can affect the central nervous system but the psychiatric manifestations are not well described. The hallmark of the disorder is an acute necrotizing inflammation of the vessel media with fibrinoid necrosis. We report a case of a 31-year-old man who had been treated for schizophrenia but was found to have vasculitides of the microscopic polyangiitis type and who improved on therapy with corticosteroids and immunosuppressive drugs. We would like to draw attention to this rare but important manifestation of vasculitis, and to the importance of its recognition.

Explore related subjects

Adrenal Cortex HormonesAdultBiopsy, NeedleCyclophosphamideDiagnosis, DifferentialDrug Therapy, CombinationFollow-Up StudiesHumansMaleSchizophreniaTreatment OutcomeVasculitis, Leukocytoclastic, CutaneousCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Askari, A Saadeh, N I Buheis. 1999. Microscopic polyangiitis presenting as schizophrenia.. https://doi.org/10.1007/s002960050087

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗
PubMed2007

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗